Generation Bio Co (Generation Bio Co) EV-to-EBITDA

: -0.15 (As of Today)

View and export this data going back to 2020. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Generation Bio Co's enterprise value is $19.67 Mil. Generation Bio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-133.30 Mil. Therefore, Generation Bio Co's EV-to-EBITDA for today is -0.15.

The historical rank and industry rank for Generation Bio Co's EV-to-EBITDA or its related term are showing as below:

GBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.98 Med: -0.11 Max: 1.17
Current: -0.15

During the past 6 years, the highest EV-to-EBITDA of Generation Bio Co was 1.17. The lowest was -0.98. And the median was -0.11.

GBIO's EV-to-EBITDA is ranked worse than
100% of 472 companies
in the Biotechnology industry
Industry Median: 9.005 vs GBIO: -0.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Generation Bio Co's stock price is $3.26. Generation Bio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.960. Therefore, Generation Bio Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Generation Bio Co EV-to-EBITDA Historical Data

The historical data trend for Generation Bio Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generation Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-13.52

-0.95

-0.27

0.43

Generation Bio Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-0.27	-0.56	-0.98	-0.30	0.43

Competitive Comparison

For the Biotechnology subindustry, Generation Bio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generation Bio Co EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Generation Bio Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Generation Bio Co's EV-to-EBITDA falls into.

Generation Bio Co EV-to-EBITDA Calculation

Generation Bio Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	19.666	/	-133.3
	=	-0.15

Generation Bio Co's current Enterprise Value is $19.67 Mil.
Generation Bio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.30 Mil.

Generation Bio Co (NAS:GBIO) EV-to-EBITDA Explanation

Generation Bio Co's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	3.26	/	-1.960
	=	At Loss

Generation Bio Co's share price for today is $3.26.
Generation Bio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.960.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Generation Bio Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Generation Bio Co (Generation Bio Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.generationbio.com

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.

Executives

Dannielle Appelhans	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson	director	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Anthony G. Quinn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Antoinette Paone	officer: CHIEF OPERATING OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Yalonda Howze	officer: CHIEF LEGAL OFFICER	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa	officer: CHIEF STRATEGY OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p.	10 percent owner	400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton	officer: Chief Scientific Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough	director, 10 percent owner, officer: See Remarks	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino	officer: Chief Operating Officer	GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142